SCHEMBL6326620

SCHEMBL6326620

CCCCN1CCC(CCC(=O)c2ccc(N)nc2OC)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR4 Q13639 15/20 0.67
ACHE P22303 7/20 0.67
MEN1 O00255 2/20 0.60
ALDH1A1 P00352 2/20 0.60
CYP2D6 P10635 2/20 0.60
CYP2C9 P11712 2/20 0.60
KMT2A Q03164 2/20 0.60
TSHR P16473 1/20 0.60
CHRM1 P11229 2/20 0.49
CHRM4 P08173 2/20 0.49
CHRM5 P08912 2/20 0.49
CHRM3 P20309 2/20 0.49
ADRA1B P35368 2/20 0.49
CHRM2 P08172 1/20 0.49
HTR1A P08908 1/20 0.49
ADRA2A P08913 1/20 0.49
DRD2 P14416 1/20 0.49
ADRA2B P18089 1/20 0.49
DRD4 P21917 1/20 0.49
ADRA1D P25100 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6330777 0.84 ACHE (0.67) HTR4ACHE
SCHEMBL6328102 0.83 HTR4 (0.70) HTR4ACHEMEN1ALDH1A1CYP2D6
SCHEMBL17709619 0.80 HTR4 (1.00) HTR4ACHEMEN1ALDH1A1CYP2D6
SCHEMBL6327293 0.80 FAAH (0.46) HTR4ACHEALDH1A1
SCHEMBL6326564 0.79 HTR4 (0.55) HTR4ACHEDRD2DRD4
SCHEMBL7259562 0.78 HTR4 (0.45) HTR4ACHEMEN1ALDH1A1CYP2D6
SCHEMBL7259567 0.76 HTR4 (0.42) HTR4ACHEMEN1ALDH1A1CYP2D6
SCHEMBL549019 0.75 HTR4 (1.00) HTR4ACHEMEN1ALDH1A1CYP2D6
SCHEMBL29604454 0.75 HTR4 (1.00) HTR4ACHEMEN1ALDH1A1CYP2D6
SCHEMBL17709630 0.75 HTR4 (1.00) HTR4ACHEMEN1ALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6979690-B2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators PFIZER INC. (US) 2005-12-27 US disclosed
US-20030207875-A1 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators PFIZER INC 2003-11-06 US disclosed
EP-1325921-A2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators Pfizer Inc. (US) 2003-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207875-A1 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators HRH4, HRH2, HTR4 HTR4 3/4885ACHE 3937/4885MEN1 4554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.